Rare diseases

Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs

Filter by content category

or

Filter by market

View all

patient-reported data

Blogs

Rare diseases

How to set up an EAP without a European presence

Expanded Access Programs

Blogs

Rare diseases

EMA orphan drug designation

real-world data

Blogs

Rare diseases

Four considerations before collecting real-world data in your EAP

rare and speciality diseases

Blogs

Rare diseases

The increasing importance of real-world data for the EMA

Real-world data

Blogs

Rare diseases

Real-world data and shaping the future of healthcare

early access program benefits

Blogs

Rare diseases

Six steps for a successful Early Access Program in Europe

patient support program in europe

Thought Leadership

Rare diseases

Get the free whitepaper: Transitioning from open-label extensions to early access programs

orphan drug development

Blogs

Rare diseases

Mitigating risks in early access programmes: A guide for biotech companies

Boys playing football

Thought Leadership

Rare diseases

Get the free whitepaper: How early access programs & real-world data help Biotechs succeed